HBK Sorce Advisory LLC Invests $2.82 Million in Arrowhead Pharmaceuticals, Inc. $ARWR

HBK Sorce Advisory LLC acquired a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 76,408 shares of the biotechnology company’s stock, valued at approximately $2,823,000. HBK Sorce Advisory LLC owned 0.06% of Arrowhead Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. CWM LLC increased its stake in shares of Arrowhead Pharmaceuticals by 6.7% in the third quarter. CWM LLC now owns 12,179 shares of the biotechnology company’s stock valued at $420,000 after purchasing an additional 764 shares during the period. Resona Asset Management Co. Ltd. grew its holdings in Arrowhead Pharmaceuticals by 8.7% in the 2nd quarter. Resona Asset Management Co. Ltd. now owns 11,218 shares of the biotechnology company’s stock worth $180,000 after buying an additional 900 shares in the last quarter. Empowered Funds LLC increased its position in Arrowhead Pharmaceuticals by 6.9% in the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock valued at $194,000 after acquiring an additional 979 shares during the period. GAMMA Investing LLC raised its stake in Arrowhead Pharmaceuticals by 64.4% during the 3rd quarter. GAMMA Investing LLC now owns 2,626 shares of the biotechnology company’s stock valued at $91,000 after acquiring an additional 1,029 shares in the last quarter. Finally, KLP Kapitalforvaltning AS boosted its position in Arrowhead Pharmaceuticals by 5.2% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 24,300 shares of the biotechnology company’s stock worth $384,000 after acquiring an additional 1,200 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Arrowhead Pharmaceuticals

In related news, Director William D. Waddill sold 8,367 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, December 19th. The stock was sold at an average price of $67.65, for a total value of $566,027.55. Following the transaction, the director directly owned 56,563 shares in the company, valued at $3,826,486.95. The trade was a 12.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Christopher Richard Anzalone sold 12,586 shares of the business’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $68.44, for a total value of $861,385.84. Following the sale, the chief executive officer directly owned 3,805,926 shares in the company, valued at $260,477,575.44. This trade represents a 0.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 368,736 shares of company stock worth $23,670,228. 4.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Morgan Stanley raised their price target on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a report on Wednesday, November 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. Royal Bank Of Canada boosted their price target on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. HC Wainwright upped their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the stock a “buy” rating in a research note on Tuesday, December 2nd. Finally, Bank of America raised their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $61.89.

Arrowhead Pharmaceuticals Stock Up 0.1%

NASDAQ ARWR opened at $70.16 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86. The company’s 50 day simple moving average is $51.76 and its 200 day simple moving average is $33.19. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $72.36. The company has a market capitalization of $9.53 billion, a P/E ratio of -876.89 and a beta of 1.28.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.